Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Verici Dx Plc

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...
Brava Health

Extending surgical expertise beyond the operating theatre

Brava is building a framework to capture retiring surgeons’ clinical judgement and convert it into durable digital infrastructure that supports continuity, training and long term healthcare resilience...
Oxford Biomedica Plc

Oxford Biomedica schedules Capital Markets Day and upcoming Investor Conferences

Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also report FY 2025 preliminary results on 26 March 2026, followed by a virtual analyst briefing...
Oxford Nanopore Technologies plc

Oxford Nanopore reports 24% revenue growth in FY2025, reaffirms path to EBITDA breakeven

Smith & Nephew plc

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%...
Physicians Capital

Physicians Capital Signs Non-Binding Exclusive LOI for Acquisition by PCMC

Hikma Pharmaceuticals plc

Hikma Pharmaceuticals delivers 2025 revenue growth in line with guidance

Hikma achieved 6% core revenue growth and maintained resilient margins in 2025, supported by strong Branded and Hikma Rx performance. The company outlined a cautious 2026 outlook, leadership changes, a 5% dividend increase, and a $250 million share buyback programme...
Brava Health

Clinical AI’s real test is trust

As scrutiny of healthcare AI intensifies, platforms built around transparency, accountability and defined clinical scope are likely to command institutional confidence and long term capital...
Haleon plc

Haleon reports 2025 results with 3% organic growth and margin expansion

Haleon delivered 3% organic revenue growth in 2025, supported by strong performance in Oral Health and emerging markets. Adjusted operating profit rose 10.5% organically, with margin expansion driven by productivity gains and disciplined investment...
Verici Dx Plc

Verici Dx upgrades genomics infrastructure to support scale

Cloud-enabled analytics are strengthening the company’s ability to process data at scale and support wider clinical adoption...
Convatec

Convatec reports 6.5% revenue growth and upgraded medium-term target

Convatec Group PLC reported FY2025 revenue of $2.44bn, up 6.5% on a reported basis, with adjusted operating profit rising 12.1% to $544m and adjusted EPS up 16%...
Cizzle Bio

Cizzle Biotechnology nears CLIA accreditation for early lung cancer test

Cizzle Biotechnology reports that its North American licensing partner, Cizzle Bio Inc, is in the final stages of CLIA accreditation for the Company’s CIZ1B lung cancer biomarker test, with submission expected in Q2 2026...
AstraZeneca

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with CLL and SLL, following Phase III data showing improved progression-free survival versus chemoimmunotherapy...
Verici Dx

Verici Dx drives commercial growth, capturing US transplant market (LON:VRCI)

CEO Sara Barrington outlines Verici Dx’s commercial progress, reimbursement milestones, and expansion plans as the company scales its RNA-based kidney transplant test across the US...
Ethtry plc

Ethtry CEO Patrick Chopard on Strategy and Ethereum Treasury (AQSE:ETHY)

Ethtry CEO Patrick Chopard outlines Ethtry plc’s operating strategy, Ethereum treasury approach, and key partnerships supporting long-term value...
GSK

GSK secures EU approval for Exdensur in severe asthma and CRSwNP

GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in patients aged 12 and older, and for adults with severe chronic rhinosinusitis with nasal polyps...
Aptamer

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system...
Verici Dx Plc

Verici Dx revenue growth signals commercial inflection point

Rising Tutivia adoption and broader US insurance coverage are strengthening revenue visibility and commercial positioning...
EDX Medical Group plc

EDX Medical raises £3.5m to accelerate prostate cancer programme

EDX Medical Group plc has completed a £3.5 million fundraising from existing high net worth shareholders, issuing 24,999,999 new ordinary shares at 14p per share...
Brava Health

Brava Health positions for the next phase of digital care integration

Brava Health is building patient-controlled digital infrastructure to simplify how people organise and act on their health information...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Verici Dx Plc

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...
Brava Health

Extending surgical expertise beyond the operating theatre

Brava is building a framework to capture retiring surgeons’ clinical judgement and convert it into durable digital infrastructure that supports continuity, training and long term healthcare resilience...
Oxford Biomedica Plc

Oxford Biomedica schedules Capital Markets Day and upcoming Investor Conferences

Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also report FY 2025 preliminary results on 26 March 2026, followed by a virtual analyst briefing...
Oxford Nanopore Technologies plc

Oxford Nanopore reports 24% revenue growth in FY2025, reaffirms path to EBITDA breakeven

Smith & Nephew plc

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%...
Physicians Capital

Physicians Capital Signs Non-Binding Exclusive LOI for Acquisition by PCMC

Hikma Pharmaceuticals plc

Hikma Pharmaceuticals delivers 2025 revenue growth in line with guidance

Hikma achieved 6% core revenue growth and maintained resilient margins in 2025, supported by strong Branded and Hikma Rx performance. The company outlined a cautious 2026 outlook, leadership changes, a 5% dividend increase, and a $250 million share buyback programme...
Brava Health

Clinical AI’s real test is trust

As scrutiny of healthcare AI intensifies, platforms built around transparency, accountability and defined clinical scope are likely to command institutional confidence and long term capital...
Haleon plc

Haleon reports 2025 results with 3% organic growth and margin expansion

Haleon delivered 3% organic revenue growth in 2025, supported by strong performance in Oral Health and emerging markets. Adjusted operating profit rose 10.5% organically, with margin expansion driven by productivity gains and disciplined investment...
Verici Dx Plc

Verici Dx upgrades genomics infrastructure to support scale

Cloud-enabled analytics are strengthening the company’s ability to process data at scale and support wider clinical adoption...
Convatec

Convatec reports 6.5% revenue growth and upgraded medium-term target

Convatec Group PLC reported FY2025 revenue of $2.44bn, up 6.5% on a reported basis, with adjusted operating profit rising 12.1% to $544m and adjusted EPS up 16%...
Cizzle Bio

Cizzle Biotechnology nears CLIA accreditation for early lung cancer test

Cizzle Biotechnology reports that its North American licensing partner, Cizzle Bio Inc, is in the final stages of CLIA accreditation for the Company’s CIZ1B lung cancer biomarker test, with submission expected in Q2 2026...
AstraZeneca

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with CLL and SLL, following Phase III data showing improved progression-free survival versus chemoimmunotherapy...
Verici Dx

Verici Dx drives commercial growth, capturing US transplant market (LON:VRCI)

CEO Sara Barrington outlines Verici Dx’s commercial progress, reimbursement milestones, and expansion plans as the company scales its RNA-based kidney transplant test across the US...
Ethtry plc

Ethtry CEO Patrick Chopard on Strategy and Ethereum Treasury (AQSE:ETHY)

Ethtry CEO Patrick Chopard outlines Ethtry plc’s operating strategy, Ethereum treasury approach, and key partnerships supporting long-term value...
GSK

GSK secures EU approval for Exdensur in severe asthma and CRSwNP

GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in patients aged 12 and older, and for adults with severe chronic rhinosinusitis with nasal polyps...
Aptamer

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system...
Verici Dx Plc

Verici Dx revenue growth signals commercial inflection point

Rising Tutivia adoption and broader US insurance coverage are strengthening revenue visibility and commercial positioning...
EDX Medical Group plc

EDX Medical raises £3.5m to accelerate prostate cancer programme

EDX Medical Group plc has completed a £3.5 million fundraising from existing high net worth shareholders, issuing 24,999,999 new ordinary shares at 14p per share...
Brava Health

Brava Health positions for the next phase of digital care integration

Brava Health is building patient-controlled digital infrastructure to simplify how people organise and act on their health information...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple